The global melanoma therapeutics market size is expected to reach USD 10.98 billion by 2030, registering a CAGR of 10.3% from 2023 to 2030. Increasing incidence of chronic diseases such as melanoma, skin cancer, and skin allergies is an important driver of the market. ![Global Melanoma Therapeutics Market]( "Global Melanoma Therapeutics Market")
According to the CDC, over 71, 943 people were affected by melanoma in 2013. The American Cancer Society estimates that this number will go up to 87, 100 in 2017, thus highlighting the need for melanoma drugs over the forecast period.
Increasing number of FDA approvals and the introduction of novel therapeutics with enhanced efficacy are also anticipated to present growth opportunities. Within a period of 6 years, i.e., from 2011 to 2016, around eight biologics have been approved for the treatment of this disease, which includes Opdivo, Yervoy, Cotellic, Zelboraf, Keytruda, Mekinist, Tafinlar, and Imlygic.
Companies are undertaking various R&D activities to find new indications for existing products and the development of innovative molecules. For instance, in September 2014, the U.S. FDA approved patented drug Keytruda (Merck & Co., Inc.) to treat metastatic melanoma, thereby extending the therapeutic application of its product. This drug was initially approved for the treatment of non-small cell lung cancer.
Furthermore, many pharmaceutical companies in the U.S., Europe, and Asia Pacific are focusing on the development of new biologics. For instance, in March 2017, Daiichi Sankyo Company, Limited announced a collaborative drug discovery project-Take a New Challenge for Drug discovery (TaNeDS)-to facilitate new drug development through collaborations. Moreover, it entered into a strategic research collaboration with AgonOX, Inc. to develop new immunotherapy drugs for the immuno-oncology segment. The approval of novel products over the forecast period is anticipated to boost the market growth.
According to the CDC, over 71, 943 people were affected by melanoma in 2013. The American Cancer Society estimates that this number will go up to 87, 100 in 2017, thus highlighting the need for melanoma drugs over the forecast period.
Increasing number of FDA approvals and the introduction of novel therapeutics with enhanced efficacy are also anticipated to present growth opportunities. Within a period of 6 years, i.e., from 2011 to 2016, around eight biologics have been approved for the treatment of this disease, which includes Opdivo, Yervoy, Cotellic, Zelboraf, Keytruda, Mekinist, Tafinlar, and Imlygic.
Companies are undertaking various R&D activities to find new indications for existing products and the development of innovative molecules. For instance, in September 2014, the U.S. FDA approved patented drug Keytruda (Merck & Co., Inc.) to treat metastatic melanoma, thereby extending the therapeutic application of its product. This drug was initially approved for the treatment of non-small cell lung cancer.
Furthermore, many pharmaceutical companies in the U.S., Europe, and Asia Pacific are focusing on the development of new biologics. For instance, in March 2017, Daiichi Sankyo Company, Limited announced a collaborative drug discovery project-Take a New Challenge for Drug discovery (TaNeDS)-to facilitate new drug development through collaborations. Moreover, it entered into a strategic research collaboration with AgonOX, Inc. to develop new immunotherapy drugs for the immuno-oncology segment. The approval of novel products over the forecast period is anticipated to boost the market growth.
Melanoma Therapeutics Market Report Highlights
- Targeted therapy segment is expected to show lucrative growth of 11.9% over the forecast periodowing to benefits such as low adverse effects and higher efficiency
- Branded drugs held a dominant share of 91.33% in 2022 of the industry because of patent exclusivity
- Biologics, such as Opdivo and Cotellic, are expected to exhibit lucrative growth over the forecast period owing to increase adoption and advantages such as improved therapeutic effects
- The patent for Yervoy will expire in 2022 in the U.S. and in 2020 in Europe. This is expected to provide growth opportunities for new market entrants
- Asia Pacific is expected to exhibit lucrative CAGR of 11.6% over the forecast period
- Key market players are increasing R&D efforts for the discovery and development of novel drugs for the treatment of melanoma
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Drug type
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
1.1.1. Product
1.1.2. Drug type
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Drug type outlook
2.2.3. Regional outlook
2.3. Competitive Insights
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Drug type outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Melanoma Therapeutics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market drivers analysis
3.3.2. Market restraints analysis
3.4. Melanoma Therapeutics Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market drivers analysis
3.3.2. Market restraints analysis
3.4. Melanoma Therapeutics Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Melanoma Therapeutics: Product Estimates & Trend Analysis
4.1. Melanoma Therapeutics Market: Key Takeaways
4.2. Melanoma Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Chemotherapy
4.3.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Immunotherapy
4.4.1. Immunotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Targeted Therapy
4.5.1. Targeted therapy estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Radiation Therapy
4.6.1. Radiation therapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.2. Melanoma Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Chemotherapy
4.3.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Immunotherapy
4.4.1. Immunotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Targeted Therapy
4.5.1. Targeted therapy estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Radiation Therapy
4.6.1. Radiation therapy market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Melanoma Therapeutics: Drug Type Estimates & Trend Analysis
5.1. Melanoma Therapeutics Market: Key Takeaways
5.2. Melanoma Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Branded Drugs
5.3.1. Branded drugs market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Generic Drugs
5.4.1. Generic drugs market estimates and forecasts, 2018 to 2030 (USD Million)
5.2. Melanoma Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Branded Drugs
5.3.1. Branded drugs market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Generic Drugs
5.4.1. Generic drugs market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Melanoma Therapeutics Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Melanoma Therapeutics Market by Region: Key Takeaways
6.3. North America
6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.6. Sweden
6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.7. Norway
6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.2. South Africa
6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.2. Melanoma Therapeutics Market by Region: Key Takeaways
6.3. North America
6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.6. Sweden
6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.7. Norway
6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.2. South Africa
6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.2.1. Bristol-Myers Squibb Company
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. AstraZeneca
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Novartis AG
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Merck & Co, Inc.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Amgen Inc.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. F. Hoffman-La Roche Ltd.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Abbott Laboratories.
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives=
List of Tables
7.2. Company/Competition Categorization
7.2.1. Bristol-Myers Squibb Company
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. AstraZeneca
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Novartis AG
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Merck & Co, Inc.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Amgen Inc.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. F. Hoffman-La Roche Ltd.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Abbott Laboratories.
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives=
List of Tables
Table 1 List of Abbreviation
Table 2 North America melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 3 North America melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 4 North America melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
Table 5 U.S. melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 6 U.S. melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 7 Canada melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 8 Canada melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 9 Europe melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 10 Europe melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 11 Europe melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
Table 12 Germany melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 13 Germany melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 14 UK melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 15 UK melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 16 France melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 17 France melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 18 Italy melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 19 Italy melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 20 Spain melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 21 Spain melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 22 Sweden melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 23 Sweden melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 24 Norway melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 25 Norway melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 26 Denmark melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 27 Denmark melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 28 Asia Pacific melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 29 Asia Pacific melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 30 Asia Pacific melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
Table 31 China melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 32 China melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 33 Japan melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 34 Japan melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 35 India melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 36 India melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 37 Thailand melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 38 Thailand melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 39 South Korea melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 40 South Korea melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 41 Latin America melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 42 Latin America melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 43 Latin America melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
Table 44 Brazil melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 45 Brazil melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 46 Mexico melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 47 Mexico melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 48 Argentina melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 49 Argentina melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 50 Middle East and Africa melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 51 Middle East and Africa melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 52 Middle East and Africa melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
Table 53 South Africa melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 54 South Africa melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 55 Saudi Arabia melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 56 Saudi Arabia melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 57 UAE melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 58 UAE melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 59 Kuwait melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 60 Kuwait melanoma therapeutics market, by drug type, (USD Million) 2018 - 2030Report SummarysSegmentationMethodologyRequest a FREE Sample Copy
s
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Drug type
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Table 3 North America melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 4 North America melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
Table 5 U.S. melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 6 U.S. melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 7 Canada melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 8 Canada melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 9 Europe melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 10 Europe melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 11 Europe melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
Table 12 Germany melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 13 Germany melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 14 UK melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 15 UK melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 16 France melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 17 France melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 18 Italy melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 19 Italy melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 20 Spain melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 21 Spain melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 22 Sweden melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 23 Sweden melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 24 Norway melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 25 Norway melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 26 Denmark melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 27 Denmark melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 28 Asia Pacific melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 29 Asia Pacific melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 30 Asia Pacific melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
Table 31 China melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 32 China melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 33 Japan melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 34 Japan melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 35 India melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 36 India melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 37 Thailand melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 38 Thailand melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 39 South Korea melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 40 South Korea melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 41 Latin America melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 42 Latin America melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 43 Latin America melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
Table 44 Brazil melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 45 Brazil melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 46 Mexico melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 47 Mexico melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 48 Argentina melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 49 Argentina melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 50 Middle East and Africa melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 51 Middle East and Africa melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 52 Middle East and Africa melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
Table 53 South Africa melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 54 South Africa melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 55 Saudi Arabia melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 56 Saudi Arabia melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 57 UAE melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 58 UAE melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 59 Kuwait melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 60 Kuwait melanoma therapeutics market, by drug type, (USD Million) 2018 - 2030Report SummarysSegmentationMethodologyRequest a FREE Sample Copy
s
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Drug type
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Drug type outlook
2.2.3. Regional outlook
2.3. Competitive Insights
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Drug type outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Melanoma Therapeutics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market drivers analysis
3.3.2. Market restraints analysis
3.4. Melanoma Therapeutics Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market drivers analysis
3.3.2. Market restraints analysis
3.4. Melanoma Therapeutics Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Melanoma Therapeutics: Product Estimates & Trend Analysis
4.1. Melanoma Therapeutics Market: Key Takeaways
4.2. Melanoma Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Chemotherapy
4.3.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Immunotherapy
4.4.1. Immunotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Targeted Therapy
4.5.1. Targeted therapy estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Radiation Therapy
4.6.1. Radiation therapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.2. Melanoma Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Chemotherapy
4.3.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Immunotherapy
4.4.1. Immunotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Targeted Therapy
4.5.1. Targeted therapy estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Radiation Therapy
4.6.1. Radiation therapy market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Melanoma Therapeutics: Drug Type Estimates & Trend Analysis
5.1. Melanoma Therapeutics Market: Key Takeaways
5.2. Melanoma Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Branded Drugs
5.3.1. Branded drugs market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Generic Drugs
5.4.1. Generic drugs market estimates and forecasts, 2018 to 2030 (USD Million)
5.2. Melanoma Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Branded Drugs
5.3.1. Branded drugs market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Generic Drugs
5.4.1. Generic drugs market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Melanoma Therapeutics Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Melanoma Therapeutics Market by Region: Key Takeaways
6.3. North America
6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.6. Sweden
6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.7. Norway
6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.2. South Africa
6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.2. Melanoma Therapeutics Market by Region: Key Takeaways
6.3. North America
6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.6. Sweden
6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.7. Norway
6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.2. South Africa
6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.2.1. Bristol-Myers Squibb Company
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. AstraZeneca
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Novartis AG
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Merck & Co, Inc.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Amgen Inc.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. F. Hoffman-La Roche Ltd.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Abbott Laboratories.
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2. Company/Competition Categorization
7.2.1. Bristol-Myers Squibb Company
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. AstraZeneca
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Novartis AG
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Merck & Co, Inc.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Amgen Inc.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. F. Hoffman-La Roche Ltd.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Abbott Laboratories.
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
List of Tables
Table 1 List of Abbreviation
Table 2 North America melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 3 North America melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 4 North America melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
Table 5 U.S. melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 6 U.S. melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 7 Canada melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 8 Canada melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 9 Europe melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 10 Europe melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 11 Europe melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
Table 12 Germany melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 13 Germany melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 14 UK melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 15 UK melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 16 France melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 17 France melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 18 Italy melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 19 Italy melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 20 Spain melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 21 Spain melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 22 Sweden melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 23 Sweden melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 24 Norway melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 25 Norway melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 26 Denmark melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 27 Denmark melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 28 Asia Pacific melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 29 Asia Pacific melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 30 Asia Pacific melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
Table 31 China melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 32 China melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 33 Japan melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 34 Japan melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 35 India melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 36 India melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 37 Thailand melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 38 Thailand melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 39 South Korea melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 40 South Korea melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 41 Latin America melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 42 Latin America melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 43 Latin America melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
Table 44 Brazil melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 45 Brazil melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 46 Mexico melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 47 Mexico melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 48 Argentina melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 49 Argentina melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 50 Middle East and Africa melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 51 Middle East and Africa melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 52 Middle East and Africa melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
Table 53 South Africa melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 54 South Africa melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 55 Saudi Arabia melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 56 Saudi Arabia melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 57 UAE melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 58 UAE melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 59 Kuwait melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 60 Kuwait melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 2 North America melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 3 North America melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 4 North America melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
Table 5 U.S. melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 6 U.S. melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 7 Canada melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 8 Canada melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 9 Europe melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 10 Europe melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 11 Europe melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
Table 12 Germany melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 13 Germany melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 14 UK melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 15 UK melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 16 France melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 17 France melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 18 Italy melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 19 Italy melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 20 Spain melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 21 Spain melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 22 Sweden melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 23 Sweden melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 24 Norway melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 25 Norway melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 26 Denmark melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 27 Denmark melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 28 Asia Pacific melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 29 Asia Pacific melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 30 Asia Pacific melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
Table 31 China melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 32 China melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 33 Japan melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 34 Japan melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 35 India melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 36 India melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 37 Thailand melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 38 Thailand melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 39 South Korea melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 40 South Korea melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 41 Latin America melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 42 Latin America melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 43 Latin America melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
Table 44 Brazil melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 45 Brazil melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 46 Mexico melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 47 Mexico melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 48 Argentina melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 49 Argentina melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 50 Middle East and Africa melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 51 Middle East and Africa melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 52 Middle East and Africa melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
Table 53 South Africa melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 54 South Africa melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 55 Saudi Arabia melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 56 Saudi Arabia melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 57 UAE melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 58 UAE melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 59 Kuwait melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
Table 60 Kuwait melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Melanoma therapeutics: market outlook
Fig. 9 Melanoma therapeutics competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Melanoma therapeutics market driver impact
Fig. 15 Melanoma therapeutics market strategic initiatives analysis
Fig. 16 Melanoma therapeutics market: Product movement analysis
Fig. 17 Melanoma therapeutics market: Product outlook and key takeaways
Fig. 18 Chemotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 19 Immunotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Targeted therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Radiation therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Melanoma therapeutics market: Drug type movement analysis
Fig. 23 Melanoma therapeutics market: Drug type and key takeaways
Fig. 24 Branded drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Generic drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Global melanoma therapeutics market: Regional movement analysis
Fig. 27 Global melanoma therapeutics market: Regional outlook and key takeaways
Fig. 28 North America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Melanoma therapeutics: market outlook
Fig. 9 Melanoma therapeutics competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Melanoma therapeutics market driver impact
Fig. 15 Melanoma therapeutics market strategic initiatives analysis
Fig. 16 Melanoma therapeutics market: Product movement analysis
Fig. 17 Melanoma therapeutics market: Product outlook and key takeaways
Fig. 18 Chemotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 19 Immunotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Targeted therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Radiation therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Melanoma therapeutics market: Drug type movement analysis
Fig. 23 Melanoma therapeutics market: Drug type and key takeaways
Fig. 24 Branded drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Generic drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Global melanoma therapeutics market: Regional movement analysis
Fig. 27 Global melanoma therapeutics market: Regional outlook and key takeaways
Fig. 28 North America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
Companies Mentioned
- Bristol-Myers Squibb Company
- AstraZeneca
- Novartis AG
- Merck & Co, Inc.
- Amgen Inc.
- F. Hoffman-La Roche Ltd.
- Abbott Laboratories.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | September 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 5.08 Billion |
| Forecasted Market Value ( USD | $ 10.98 Billion |
| Compound Annual Growth Rate | 10.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 7 |
